SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Garth Richmond who wrote (364)12/23/1998 1:06:00 PM
From: Ian@SI  Read Replies (1) of 1321
 
Nice story.

The market seems to like it with a new 52 week high being set for QLT.

However, I suspect that the Phase III results from the AMD trial are being leaked and that they're very good.

For AMD, there's no alternate treatment. Most people would do anything to preserve their eyesight.

For most cancers that PDTs are applicable, there is an alternative treatment that doesn't require capital expenditures by hospitals for lasers or specially trained technicians to acquire additional skills.

Don't get me wrong. I think these cancer treatments will generate revenue. But I think once the hospitals get the lasers and the trained technicians for AMD, the cancer treatments are more likely to experience rapid growth. Until then, it's a difficult additional expenditure to justify especially when the people who approve the expense are resistant to any type of change.

IMO,
Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News